1.30

6.56% +0.08

Passage Bio Inc (PASG)

Overview News Price History Option Chain Discussions Forecast

Passage Bio Inc stock is currently priced at $1.30, with a 24-hour trading volume of 68,819. It has seen a +6.56% increased in the last 24 hours and a +2.36% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.23 pivot point. If it approaches the $1.31 resistance level, significant changes may occur.

Previous Close:

$1.22

Open:

$1.22

24h Volume:

68,819

Market Cap:

$78.86M

Revenue:

Net Income/Loss:

$-112.38M

P/E Ratio:

-0.6341

EPS:

-2.05

Net Cash Flow:

$-83.38M

1W Performance:

+13.04%

1M Performance:

+2.36%

6M Performance:

+100.00%

1Y Performance:

+36.63%

1D Range:

$1.22

$1.32

52W Range:

$0.5751

$1.79

Passage Bio Inc Stock (PASG) Company Profile

Name

Passage Bio Inc

Sector

Healthcare (1203)

Industry

Biotechnology (688)

Phone

267 866 0311

Address

One Commerce Square, 39th Floor 2005 Market Street, Philadelphia, PA

Employee

133

Twitter

@passage_bio

Next Earnings Date

2024-05-21

Latest SEC Filings

PASG's Discussions on Twitter

Passage Bio Inc Stock (PASG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-08-22	Downgrade	JP Morgan	Overweight → Neutral
Jan-19-22	Downgrade	Goldman	Buy → Neutral
Jul-01-21	Initiated	Raymond James	Outperform
Jun-15-21	Initiated	BTIG Research	Buy
Mar-04-21	Upgrade	Goldman	Neutral → Buy
Feb-04-21	Initiated	Guggenheim	Buy
Jan-25-21	Initiated	Wedbush	Outperform
Jan-04-21	Upgrade	JP Morgan	Neutral → Overweight
Dec-11-20	Initiated	Citigroup	Neutral
Aug-14-20	Downgrade	JP Morgan	Overweight → Neutral
Jun-25-20	Downgrade	Goldman	Buy → Neutral
Mar-25-20	Initiated	Chardan Capital Markets	Buy
Mar-24-20	Initiated	Cowen	Outperform
Mar-24-20	Initiated	Goldman	Buy
Mar-24-20	Initiated	JP Morgan	Overweight

View All

Passage Bio Inc Stock (PASG) Latest News

Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit

GlobeNewswire Inc.

Passage Bio Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Recent Business Highlights

GlobeNewswire Inc.

Passage Bio to Participate in Upcoming Investor Conferences

GlobeNewswire Inc.

Passage Bio to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire Inc.

Why BlackBerry Shares Are Trading Lower By Over 5%; Here Are 20 Stocks Moving Premarket

Benzinga

Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

GlobeNewswire Inc.

Passage Bio Inc Stock (PASG) Financials Data

Passage Bio Inc (PASG) Net Income 2024

PASG net income (TTM) was -$112.38 million for the quarter ending September 30, 2023, a +29.86% increase year-over-year.

Passage Bio Inc (PASG) Cash Flow 2024

PASG recorded a free cash flow (TTM) of -$83.38 million for the quarter ending September 30, 2023, a +39.18% increase year-over-year.

Passage Bio Inc (PASG) Earnings per Share 2024

PASG earnings per share (TTM) was -$2.05 for the quarter ending September 30, 2023, a +30.74% growth year-over-year.

Passage Bio, Inc., a genetic medicines company, develops transformative therapies for central nervous system diseases. It develops PBGM01, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GLB1 gene encoding lysosomal acid beta-galactosidase for infantile GM1; PBFT02, which utilizes an AAV1 capsid to deliver to the brain a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD-GRN; and PBKR03, which utilizes a proprietary, AAVhu68 capsid to deliver to the brain and peripheral tissues a functional GALC gene encoding the hydrolytic enzyme galactosylceramidase for infantile Krabbe disease. The company also develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and PBCM06 for the treatment of Charcot-Marie-Tooth Type 2A. Passage Bio, Inc. has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. The company was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.